Cold-EEZE Claims Chilled By Zicam Maker’s NAD Challenge
This article was originally published in The Tan Sheet
NAD says ProPhase should alter claims about how much Cold-EEZE reduces the duration of colds, in a decision on a case brought by competitor Matrixx Initiatives. The advertising watchdog group calls for tweaks to a number of ProPhase’s claims.
You may also be interested in...
Matrixx aims to make more consumers aware they can shorten the duration of a cold rather than treat the symptoms without affecting how long the cold lasts. New advertising introduces the “Cold Monster” to remind consumers to use Zicam products when they feel the first signs of a “monster of a cold.”
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.